Pancreatin added to usual diabetes medicines in people with type 2 diabetes
Tests pancreatin alongside usual medicines in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes
Key facts
- Where
- Zabrze, PolandSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who have had it for at least 12 months. It tests pancreatin added to their usual diabetes treatment.
- Age
- 35 to 75 years
- Sex
- All sexes
- Disease stage
- Type 2 diabetes diagnosed for at least 12 months, with HbA1c between 6.5% (48 mmol/mol) and 9.0% (75 mmol/mol)
- Earlier treatment
- Must be treated with oral antihyperglycemic agents and/or insulin, alone or combined. Must not have used incretin-based drugs now or in the last 3 months.
- Biomarker or test result
- HbA1c between 6.5% (48 mmol/mol) and 9.0% (75 mmol/mol)
Main reasons for not taking part
- Type 1 diabetes
- Incretin-based drugs (GLP-1 receptor agonists, dual GIP and GLP-1 receptor agonists, DPP-4 inhibitors) now or within the last 3 months
- History of pancreatic surgery
- History of chronic pancreatitis
- History of acute pancreatitis
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 75 years old?
Source: NCT07852988, who can take part
Where in Poland
- Department of Internal Medicine, Diabetology and Cardiometabolic Disorders, Faculty of Medical Sciences ZabrzeZabrze, PolandContact: Marta Wróbel, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Silesian Centre for Heart Diseases
- Trial code
- NCT07852988
- Record updated
- 1 October 2026
- Original description
Medications that enhance the incretin effect (GLP-1 receptor agonists, tirzepatide (GIP/GLP-1 receptor agonist) and DPP-4 inhibitors) are used in treatment of patients with type 2 diabetes. GLP-1 agonists and tirzepatide not only effectively lower blood glucose levels but also promote weight loss-primarily by stimulating the satiety center in the central nervous system - and reduce cardiovascular risk. Evidence suggests that oral pancreatin supplementation also enhances the incretin effect by increasing GIP and GLP-1 concentrations, and consequently insulin levels, which translates into a reduction in postprandial glycemia in patients with cystic fibrosis or chronic pancreatitis. In our study we aim to evaluate the impact of pancreatin on the incretin effect and glycemic control in patients with type 2 diabetes without exocrine pancreatic insufficiency.Read full original descriptionShow less
The Effect of Pancreatin Added to Standard Antihyperglycemic Therapy on Metabolic Control in Patients With Type 2 Diabetes
Medications that enhance the incretin effect (GLP-1 receptor agonists, tirzepatide (GIP/GLP-1 receptor agonist) and DPP-4 inhibitors) are used in treatment of patients with type 2 diabetes. GLP-1 agonists and tirzepatide not only effectively lower blood glucose levels but also promote weight loss-primarily by stimulating the satiety center in the central nervous system - and reduce cardiovascular risk. Evidence suggests that oral pancreatin supplementation also enhances the incretin effect by increasing GIP and GLP-1 concentrations, and consequently insulin levels, which translates into a reduction in postprandial glycemia in patients with cystic fibrosis or chronic pancreatitis. In our study we aim to evaluate the impact of pancreatin on the incretin effect and glycemic control in patients with type 2 diabetes without exocrine pancreatic insufficiency.
Inclusion: Type 2 diabetes diagnosed for at least 12 months; Patients treated with oral antihyperglycemic agents and/or insulin as monotherapy or combination therapy; Age between 35 and 75 years; HbA1c: 6.5% - 9.0%.
Exclusion: Use of incretin-based drugs (GLP-1 receptor agonists, dual GIP and GLP-1 receptor agonists, DPP-4 inhibitors) currently or within the last 3 months; Type 1 diabetes; History of pancreatic surgery; History of chronic pancreatitis; History of acute pancreatitis.